Shopping Cart
Specialist article · Analytics & standardization
Beyond platelet count: what the PRP proteome and metabolome reveal
PRP is not a uniformly composed preparation. Platelet count, leukocyte content, plasma matrix and processing explain only part of its biological variability. Proteomics and metabolomics reveal additional differences: recent studies describe formulation-specific protein and metabolic signatures and early biomarkers associated with clinical response. What research has not yet established is a routine rule of the form “this molecular profile = this PRP protocol for this patient”.
716proteins identified in TRAP-stimulated platelet releasate; 225 were reproducibly detected in all donors studied
~600proteins detected across plasma, PRP and PPP, with more than 50% overlap between fractions
10 bnbillion platelets discussed in knee-osteoarthritis studies as a possible dose threshold, not a universal dosing rule
30differentially expressed proteins reported between responders and non-responders in a small PRP cohort
Why counting a few growth factors is no longer enough
The common explanatory model for Platelet-Rich Plasma (PRP) focuses on a handful of growth factors such as PDGF, TGF-β, VEGF, EGF, IGF-1 and bFGF. Analytically, that is a major simplification. Mass-spectrometry studies of stimulated platelet releasate have identified hundreds of proteins, including matrix proteins, proteases, inflammatory mediators and proteins associated with extracellular vesicles.
A direct comparison of plasma, leukocyte-poor PRP and platelet-poor plasma detected almost 600 proteins in total, with more than half shared across fractions. This matters because a substantial part of what is measured in PRP is the plasma proteome rather than platelet-derived secretion alone. Two preparations with a similar platelet count can therefore differ in molecular composition.
Analytical consequence
Low-abundance proteins that may distinguish preparations are easily masked by albumin and immunoglobulins. Sample handling also matters: platelets can activate ex vivo during processing and release proteins and vesicles. Proteomic results therefore depend not only on the donor but also on pre-analytics, activation state and analytical method.
Three molecular layers of a PRP preparation
LEVEL 1
Proteome
Growth factors, cytokines, matrix proteins, proteases, alarmins and plasma proteins.
Answers: What proteins and mediators are present or released?
LEVEL 2
Metabolome
Energy intermediates, amino acids, lipid mediators, redox and steroid metabolites.
Answers: What metabolic state and pathway pattern is visible?
LEVEL 3
Vesicle fraction
EV proteins, miRNA cargo, protein corona and even transferred organelles.
Answers: How can biological information be transported between cells?
These levels are complementary, not interchangeable. A small ELISA growth-factor panel cannot describe redox state, broad metabolic pathways or vesicle-mediated transfer.
Analytical depth at a glance
Each square represents one of the roughly 716 proteins identified in stimulated platelet releasate. Select an analytical method.
5proteins covered
0.7 %coverage of the identified releasate
711not covered
Schematic representation. The reference is the reported size of the platelet-releasate proteome. Multiplex panels may include analytes outside this dataset. Broader analytical coverage does not automatically mean greater clinical relevance.
What metabolomics shows about PRP preparation systems
An exploratory 2025 study used untargeted Q-TOF LC-MS to compare ten PRP preparations. Part of the design included several preparations generated from the blood of a single donor, allowing preparation-related differences to be examined without inter-individual blood variability. This is particularly relevant to standardized PRP processing.
The formulations differed in pathways related to inflammatory signaling, redox homeostasis, steroid metabolism, energy production and platelet activation. Even preparations made from the same donor separated in multivariate analysis. The finding supports a clear point: the preparation method can measurably shape the biochemical profile. It does not prove that one formulation is clinically superior.
Chemically activated PRP (A-PRP)
bilirubinarachidonic acidcoproporphyrinogencreatine
The authors associated this pattern with redox buffering, early inflammatory activation and energy availability. The interpretation is exploratory and does not constitute a clinically validated indication assignment.
Leukocyte-rich PRP (L-PRP)
L-tyrosineD-glucuronic acidnicotinamide riboside
Higher levels of several metabolites were interpreted as an immune-activation and tissue-remodeling pattern. A clinical rule selecting L-PRP on that basis has not been validated.
Leukocyte-poor PRP (P-PRP)
lower L-tyrosinelower D-glucuronic acidless inflammatory profile
Compared with L-PRP, lower levels of several inflammation- and remodeling-associated metabolites were reported. Whether that translates into a clinically preferable formulation for a specific indication remains open.
PRP formulation with hyaluronic-acid component (TFF-PRP)
carnosineL-valinedocosahexaenoic acidtestosterone glucuronide
The study reported metabolites associated with antioxidant capacity, remodeling and anabolic signaling. The metabolomic analysis itself did not demonstrate a clinical advantage.
The methodologically important point
The groups were not separated because unique metabolites appeared in only one preparation. Many of the same metabolites were present across formulations, but in different relative abundances. The research question is therefore increasingly about molecular ratios and pathway patterns, not a simplistic list of “ingredients”.
A similar principle applies to Platelet-Rich Fibrin (PRF), which should not be treated as identical to PRP. Proteomic comparisons have reported formulation-specific signatures between PRP, PRF and different PRF protocols. These data describe biological differences; they do not establish a general superiority of one platelet concentrate.
Compare formulation profiles
Ordinal visualization of the four formulations along pathways that separated in the metabolomic enrichment analysis.
No measured effect sizes are shown. The levels are an ordinal visualization of how the study authors interpreted discriminating metabolites and enriched pathways. They are useful for understanding biochemical differences, not for choosing a preparation for an individual patient.
The vesicle fraction: why growth factors cannot explain everything
Protein cargo
Proteomic analyses of platelet-derived extracellular vesicles identify proteins linked to immune defense, vesicle-mediated transport and tissue-repair pathways. The vesicle fraction therefore contains information that is missed by a small soluble growth-factor panel.
Nucleic acids
PRP-derived extracellular vesicles can carry platelet-associated microRNAs such as miR-24, miR-223 and miR-126 into recipient cells. Altered circRNA profiles after platelet activation have also been described.
Organelles
Platelets can release functional mitochondria and mitochondria-containing vesicles. This illustrates how cell-to-cell signaling can extend beyond soluble proteins and classical growth factors.
More purification is not automatically better
Work on platelet lysate and extracellular vesicles suggests that biological activity may result from an interaction between vesicles and soluble proteins. In some experimental models, highly purified vesicles were less active until the soluble fraction was added back. This is an important warning against equating analytical purity with greater biological effect.
Variability: preparation and donor both shape the molecular profile
The strongest practical message from current omics research is that PRP variability has more than one source. Preparation technique can create distinct biochemical profiles even when donor variability is held constant. At the same time, donor age, sex, baseline platelet count and comorbidities can influence platelets and soluble mediators. The literature is not fully consistent, so these variables should be documented rather than converted into simplistic treatment rules.
| Cohort / factor | Reported finding | Interpretation |
|---|---|---|
| Weibrich et al., n=115 | Growth-factor levels varied widely and correlated only weakly with platelet count; most age and sex associations were not clear. | Large inter-individual variation |
| Japanese LP-PRP cohort, n=39 | Age correlated negatively with some factors, while PRP platelet count correlated with several growth factors. | Age and baseline biology can matter |
| US cohort, n=102 | Several measured growth factors were higher in women and younger participants. | Possible demographic effects |
| Ageing platelet proteome | Mass-spectrometry studies report age-related differences in platelet protein expression. | Cell state changes with age |
| Diabetes / metabolic disease | Platelet proteomes can differ in metabolic disease, including inflammatory and haemostatic mediators. | Comorbidity may matter |
A relatively straightforward parameter is the absolute platelet dose. A 2024 systematic review found signals of a dose-response relationship in knee osteoarthritis and discussed cumulative doses above roughly 10 billion platelets as a possible threshold range in that specific literature. Heterogeneity is substantial, however, and this must not be turned into a universal dosing rule for other indications or PRP systems. For broader clinical context, see PRP therapy: mechanisms, evidence and limitations.
Calculate the platelet dose
This model illustrates how processed blood volume, baseline platelet count and platelet recovery determine the theoretical absolute platelet amount. It is not a treatment or product recommendation.
Volume of blood used to prepare the concentrate
Baseline count expressed as ×10³/µl
Proportion of platelets recovered in the concentrate
Final plasma volume used in the calculation
010 bn (threshold discussed in knee-OA literature)15 bn
6.00bn platelets in the calculated preparation
1500×10³/µl in the concentrate
6.0×fold enrichment vs. whole blood
ADEPA dose category
Calculation model only. Absolute platelet amount = baseline platelet count × processed blood volume × recovery. Actual recovery is device-, protocol- and operator-dependent. The 10-billion value is discussed in parts of the knee-osteoarthritis literature and is not a universal dosing target.
Responder signatures: early clues to possible biomarkers
A 2026 knee-osteoarthritis cohort compared the injected PRP of clinical responders and non-responders using mass cytometry and mass spectrometry. Thirty proteins were reported as differentially expressed. Several immune-cell populations and proteins correlated with change in KOOS pain score. This is one of the more direct demonstrations that the molecular composition of PRP may contain information related to treatment response.
| Marker | Biological context | Reported correlation with Δ KOOS pain |
|---|---|---|
| S100A8 | Calprotectin subunit / alarmin | r = 0.65, positive |
| Cathepsin G | Neutrophil serine protease | r = 0.51, positive |
| Glutathione peroxidase 1 | Antioxidant enzyme | r = −0.55, negative |
| Integrin-linked kinase | Adhesion and signaling protein | r = −0.50, negative |
The result is scientifically interesting because positive associations with neutrophil-related proteins do not fit a simple rule that “leukocyte-poor is always better”. It also illustrates why individual indication, inflammatory phenotype and preparation composition need to be separated when interpreting PRP studies.
The limitation that must stay visible
The responder analysis comes from a small cohort and has not yet been prospectively validated in an independent population. Correlation does not establish causality. The markers may reflect the patient’s inflammatory phenotype rather than a component that should be deliberately increased in PRP. At present, they are research signals, not clinical selection tests.
What still stands between omics and personalized PRP
Analytical coverage
Untargeted metabolomics captures thousands of features, but only a subset can be confidently annotated. Proteins, cytokines, cells and vesicles are not simultaneously measured unless a true multi-omics design is used.
Turnaround time
Mass spectrometry is not a practical point-of-care test before a routine PRP procedure. Near-term translation is more likely to come from smaller validated biomarker panels derived from discovery datasets.
Reporting quality
Studies often omit basic preparation details. Without platelet dose, final volume, leukocyte content, activation and centrifugation parameters, molecular findings cannot be compared reliably across studies.
External validation
A signature discovered in one indication or one preparation system cannot simply be transferred to another. Prospective cohorts and independent validation are required before predictive use.
What the main reporting systems describe
- PAW / DEPA — platelet concentration or dose, leukocytes, activation, efficiency and purity depending on the system.
- PLRA — platelets, leukocytes, red cells and activation as a minimum characterization set.
- MARSPILL — expands characterization to workflow and procedural variables.
- MIBO — a reporting standard rather than a PRP class; it focuses on methodological completeness and transparency.
How strong is the evidence?
Supported
Preparation methods can generate reproducibly different protein and metabolite signatures. PRP formulations should therefore not be assumed to be molecularly identical. In knee osteoarthritis, platelet dose may also be clinically relevant.
Plausible, not validated
Proteomic or metabolomic signatures may eventually help identify responder phenotypes or select a formulation. Existing responder datasets are small and lack prospective external validation.
Still open
It remains unclear whether reported biomarkers are causal, how stable signatures are over time, whether they transfer between indications, and which reduced tests could work at the point of care.
What this means for documentation today
Even before omics-guided personalization becomes clinically practical, the current data support more disciplined documentation. Molecular research is difficult to interpret when the basic preparation process is poorly described. In routine professional workflows, the following variables make results more comparable:
- Record absolute platelet dose where possible, not only a fold-enrichment value. Concentration without final volume does not describe the administered platelet quantity.
- Document baseline platelet count and final PRP volume. They are needed to interpret recovery and concentration.
- Record leukocyte content or formulation class. “PRP” alone does not identify the cellular composition.
- Report centrifugation in RCF, not RPM alone. Rotor radius determines the force generated at a given speed. See PRP centrifugation: RCF, RPM and time.
- Document activation, additives and tube system. The tube and its additives are part of the preparation method.
- Record processing time and handling. Pre-analytical conditions can alter platelet activation and molecular profiles.
↗PRP tubesTube systems for professional PRP preparation with product-specific information on material, additives and protocol.↗PRP centrifugesCentrifuges for professional practice and laboratory workflows with technical information on rotor, RCF and compatibility.↗Tube + centrifuge as a systemTechnical guide to compatibility, RCF, RPM, rotor radius and reproducible PRP processing.